Oruka Therapeutics, Inc. Additional Paid in Capital, Common Stock
Oruka Therapeutics, Inc. (ORKA) had Additional Paid in Capital, Common Stock of $225.99 million as of 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2024-08-01
- 2024-06-30: Additional Paid in Capital, Common Stock $225.99M.
- 2024-03-31: Additional Paid in Capital, Common Stock $225.86M.
- 2023-12-31: Additional Paid in Capital, Common Stock $225.75M.
- 2023-09-30: Additional Paid in Capital, Common Stock $225.61M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2024-06-30 | $225.99M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $225.86M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $225.75M 10-Q · filed 2024-08-01 | |
| 2023-09-30 | $225.61M 10-Q · filed 2023-10-18 | |
| 2023-06-30 | $225.45M 10-Q · filed 2023-07-21 | |
| 2023-03-31 | $225.26M 10-Q · filed 2023-04-24 | |
| 2022-12-31 | $225.06M 10-K · filed 2024-02-01 | |
| 2022-09-30 | $224.94M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $224.84M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $224.67M 10-Q · filed 2022-05-02 | |
| 2021-12-31 | $224.50M 10-K · filed 2023-02-24 | |
| 2021-09-30 | $224.39M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $224.28M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $224.15M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $200.66M 10-K · filed 2022-03-14 | |
| 2020-09-30 | $199.47M 10-Q · filed 2020-11-02 | |
| 2020-06-30 | $157.34M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $152.04M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $152.02M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $151.99M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $151.22M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $147.91M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $144.97M 10-K · filed 2020-02-18 | $144.95M 10-K · filed 2019-02-27 |
| 2018-09-30 | $144.89M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $144.84M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $144.78M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $141.27M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $141.15M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $137.11M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $134.88M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $134.72M 10-K · filed 2018-03-22 | |
| 2016-09-30 | $134.74M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $134.48M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $134.28M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $134.13M 10-K · filed 2017-03-21 | |
| 2015-09-30 | $133.98M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $133.78M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $99.47M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $99.36M 10-K · filed 2016-03-17 | $99.34M 10-K · filed 2015-03-19 |
| 2013-12-31 | $90.50M 10-K · filed 2015-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |